A restricted population of CB1 cannabinoid receptors with neuroprotective activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 22, 2014, Pages 8257-8262

  Chiarlone, Anna ^a,b   Bellocchio, Luigi ^a,b   Blázquez, Cristina ^a,b   Resel, Eva ^a,b   Soria Gómez, Edgar ^c   Cannich, Astrid ^c   Ferrero, José J ^b   Sagredo, Onintza ^a,b   Benito, Cristina ^d   Romero, Julián ^d   Sánchez Prieto, José ^b   Lutz, Beat ^e   Fernández Ruiz, Javier ^a,b   Galve Roperh, Ismael ^a,b   Guzmán, Manuel ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Excitotoxicity; Neuromodulation; Neuroprotection

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CANNABINOID 1 RECEPTOR; CRE RECOMBINASE; QUINOLINIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; CAENORHABDITIS ELEGANS PROTEIN; ENDOCANNABINOID; GAB 1 PROTEIN, C ELEGANS; GAB-1 PROTEIN, C ELEGANS; GLUTAMIC ACID; INTEGRASE; NEUROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; GENE DELETION; GLUTAMATERGIC NERVE CELL; HUNTINGTON CHOREA; LOCOMOTION; MOUSE; NERVE CELL; NERVE DEGENERATION; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PYRAMIDAL TRACT; SYNAPSE; AGED; ANIMAL; BRAIN CORTEX; CYTOLOGY; DEGENERATIVE DISEASE; FEMALE; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; NEUROMODULATION; ORGAN CULTURE TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTOSOME;

EXCITOTOXICITY; NEUROMODULATION; NEUROPROTECTION;

AGED; ANIMALS; CAENORHABDITIS ELEGANS PROTEINS; CEREBRAL CORTEX; CORPUS STRIATUM; ENDOCANNABINOIDS; FEMALE; GABAERGIC NEURONS; GLUTAMIC ACID; HUMANS; INTEGRASES; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NEURONS; NEUROTOXINS; ORGAN CULTURE TECHNIQUES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GABA-A; SYNAPTOSOMES;

EID: 84901843938     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400988111     Document Type: Article

References (42)

1. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4(11):873-884.
2. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76(1):70-81.
3. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11(12): 4213-4225. (Pubitemid 30009252)
4. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309-380.
5. Katona I, Freund TF (2008) Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14(9):923-930.
6. Gowran A, Noonan J, Campbell VA (2011) The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neurosci Ther 17(6):637-644.
7. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R (2011) Endocannabinoids and traumatic brain injury. Br J Pharmacol 163(7):1402-1410.
8. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104(12):5163-5168. (Pubitemid 47186193)
9. Lee HM, Giguere PM, Roth BL (2014) DREADDs: Novel tools for drug discovery and development. Drug Discov Today 19(4):469-473.
10. Alexander GM, et al. (2009) Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63(1):27-39.
11. Kreitzer AC (2009) Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 32(1):127-147.
12. Fernández-Ruiz J, et al. (2011) Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163(7):1365-1378.
13. Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98(4):705-713. (Pubitemid 30417587)
14. McCaw EA, et al. (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington' s disease transgenic mice. Eur J Biochem 271(23-24):4909-4920. (Pubitemid 40065594)
15. Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36(4): 577-584. (Pubitemid 24309369)
16. GlassM, DragunowM, Faull RL (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97(3):505-519. (Pubitemid 30320757)
17. 1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol Dis 45(3):983-991.
18. Blázquez C, et al. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134(pt 1):119-136.
19. Mievis S, Blum D, Ledent C (2011) Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 42(3):524-529.
20. Scammell TE, et al. (2003) Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J Neurosci 23(13):5762-5770. (Pubitemid 36807855)
21. Ahmed BY, et al. (2004) Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neurosci 5:4.
22. Monory K, et al. (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51(4):455-466. (Pubitemid 44209321)
23. Menalled L, et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 35(3):319-336.
24. Morton AJ, et al. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 33(3):331-341.
25. Steindel F, et al. (2013) Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. J Neurochem 124(6):795-807.
26. 9-tetrahydrocannabinol in mice. PLoS Biol 5(10):e269.
27. Bellocchio L, et al. (2010) Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 13(3):281-283.
28. B receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37(12):2624-2634.
29. Raymond LA, et al. (2011) Pathophysiology of Huntington's disease: Time-dependent alterations in synaptic and receptor function. Neuroscience 198(1):252-273.
30. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL (2013) Excitotoxicity: Bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698(1-3): 6-18.
31. Milnerwood AJ, et al. (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington' s disease mice. Neuron 65(2):178-190.
32. Okamoto SI, et al. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15(12):1407-1413.
33. Maccarrone M, Battista N, Centonze D (2007) The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. Prog Neurobiol 81(5-6):349-379. (Pubitemid 46528640)
34. Dowie MJ, Scotter EL, Molinari E, Glass M (2010) The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacol Ther 128(2):305-323.
35. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M (2008) Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 14(23):2279-2288.
36. Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367(1607):3353-3363.
37. Mangiarini L, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493-506. (Pubitemid 26374323)
38. Puighermanal E, et al. (2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12(9):1152-1158.
39. Palazuelos J, et al. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132(pt 11):3152-3164.
40. Mulder J, et al. (2008) Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci USA 105(25):8760-8765. (Pubitemid 351987753)
41. Martín R, et al. (2010) The metabotropic glutamate receptor mGlu7 activates phospholipase C, translocates munc-13-1 protein, and potentiates glutamate release at cerebrocortical nerve terminals. J Biol Chem 285(23):17907-17917.
42. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27(9):2396-2402.